Clinical Study Of Treatment Of Cardiogenic Shock By Traditional Medicine Decoction

ObjectiveTo evaluate the efficacy of Poge Jiuxin Decoction in patients with cardiogenic shock furtherly and objectively,a prospective,randomized controlled trial was conducted to monitor the blood of patients with cardiogenic shock by echocardiography and pulse wave indicator continuous cardiac output monitoring.The effects of flow dynamics,tissue perfusion,etc.,and health economics and 28-day survival rate,half-year survival rate evaluation,provide an objective basis for TCM treatment and new drug development research of cardiogenic shock.MethodsThis study was a prospective randomized controlled clinical study.During the period from March 2017 to December 2018,the ICU of the DDE Road General Hospital of Guangdong Provincial Hospital of Chinese Medicine met the inclusion criteria for cardiogenic shock patients.n=40)and the treatment group(n=40),the control group was treated with conventional western medicine plus warm water placebo,and the treatment group was treated with Western medicine treatment.The observation indicators included pre-treatment and the fifth day after treatment.Hemodynamic parameters such as MAP,LVEF,CO,Cl,CVP,urine volume,oxygen metabolism indicators such as blood pH,Pa02,Sa02,Ca02,D02,lactic acid,etc.,cardiac function indicators Pro-BNP,heart enzyme,muscle Calcium protein,inflammation indicators such as WBC,neutrophil percentage and CRP;and compare the hospitalization days(d)in the intensive care unit and the 30-day and 180-day mortality(%)in the two groups;Statistical analysis was compared to assess its clinical efficacy.Results1.Before treatment,there was no significant difference between the experimental group and the control group and the evaluation indexes of each efficacy(P>0.05)·2.After 5 days of treatment,the efficacy indexes of the two groups of patients were significantly improved compared with those before treatment,especially MAP,LVEF,CO,Cl,CVP and urine volume DO2,LAC,Pro-BNP,CK,CKMB,LDH,AST,WBC,neutrophil ratio and CRP were significantly different from those before treatment(P<0.05).These results indicate that it is sufficient for the general management of patients with cardiogenic shock in the clinical course.3.After treatment,the MAP,LVEF,CO,Cl,CVP,urine output,LAC and other indicators were more evident in the experimental group than in the control group,and the difference was significant(P<0.05),which indicates that the treatment of Poge Jiuxin Decoction can significantly improve hemodynamic parameters,improve cardiac output and improve myocardial oxygen consumption.However,it has a limited effect on improving oxygen metabolism,cardiac function,and reducing inflammation indicators.4.In the control group,7 patients died within 30 days,and the mortality rate was 17.50h.In the experimental group,5 patients died within 30 days,and the mortality rate was 12.5%.The mortality of the experimental group was lower than that of the control group,but the difference was not noticeable(P>0.05),which may could ascribe to the too small sample size.5.There was no significant difference in the incidence of adverse events between the two groups during the treatment,and the changes of liver and kidney function and blood pressure before and after treatment(P>0.05),indicating that the safety of the Poge Jiuxin Decoction is better.6.In this trial,there was no significant difference in ICU stay and hospitalization costs between the two groups(P>0.05).ConclusionTreating cardiogenic shock with Poge Jiuxin Decoction combined with conventional therapy can improve hemodynamics,increase tissue perfusion,and promote oxygen supply;reduce Pro-BNP a little,improve heart function,shorten ICU stay,and reduce death during hospitalization rate,but the effect is limited.The incidence of the complication of Poge Jiuxin Decoction is low,and the safety of clinical use is high.However,it is necessary to expand the sample size further and improve the quality of the research.Further research on the clinical efficacy of Paige Jiuxin Decoction will lead to higher quality clinical evidence.